TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceutica… Read more
TCM Biotech International Corp. (4169) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, TCM Biotech International Corp. (4169) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.71 Million) by net assets (NT$1.06 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TCM Biotech International Corp. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how TCM Biotech International Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TCM Biotech International Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TCM Biotech International Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Kaier New Materials
SHE:300234
|
0.026x |
|
Fluxys Belgium
BR:FLUX
|
0.140x |
|
POSCO M-TECH Co. Ltd
KQ:009520
|
-0.006x |
|
Zhejiang Wufangzhai Industry Co. Ltd. A
SHG:603237
|
N/A |
|
Horizon Kinetics Holding Corporation
PINK:HKHC
|
-0.009x |
|
Unit Corporation
PINK:UNTC
|
0.112x |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
0.082x |
|
Refrigeration Electrical Engineering Corp
VN:REE
|
0.044x |
Annual Cash Flow Conversion Efficiency for TCM Biotech International Corp. (2019–2024)
The table below shows the annual cash flow conversion efficiency of TCM Biotech International Corp. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.06 Billion | NT$167.42 Million | 0.158x | +544.32% |
| 2023-12-31 | NT$1.06 Billion | NT$-37.54 Million | -0.036x | -136.55% |
| 2022-12-31 | NT$536.67 Million | NT$52.24 Million | 0.097x | +229.14% |
| 2021-12-31 | NT$518.22 Million | NT$15.33 Million | 0.030x | -79.58% |
| 2020-12-31 | NT$517.24 Million | NT$74.90 Million | 0.145x | +454.04% |
| 2019-12-31 | NT$510.71 Million | NT$-20.89 Million | -0.041x | -- |